Nektar Therapeutics withdrew the application for the company’s opioid painkiller for adults with chronic low back pain, after a U.S. Food and Drug Administration panel unanimously voted against the drug’s approval.
Insights into former president Richard Sackler’s control of Purdue Pharma and his aggressive stance on marketing OxyContin were revealed when internal company documents were unsealed following a four-year court battle in Kentucky.
Federal prosecutors are investigating six pharmaceutical companies for potential criminal charges in connection with shipping large quantities of opioid painkillers that contributed to a healthcare crisis, according to regulatory filings.
A recent report from the Associated Press alleges the Sackler family is using similar marketing tactics to push sales of OxyContin in China through another company they own, Mundipharma.
An Oklahoma judge said Johnson & Johnson must pay that state $465 million for fueling the opioid epidemic through the deceptive marketing of painkillers, down from his original award of $572 million.
Purdue Pharma LP and the company’s Sackler family owners will be shielded until April 8, 2020, from sprawling opioid litigation to give the maker of OxyContin time to try to reach a legal settlement the drug manufacturer says is worth $10 billion.
Johnson & Johnson will pay $20.4 million to settle claims by two Ohio counties, allowing the U.S. healthcare giant to avoid an upcoming federal trial seeking to hold the industry responsible for the nation’s opioid epidemic.
An Oklahoma judge ordered Johnson & Johnson to pay $572.1 million to the state for the company’s part in fueling an opioid epidemic by deceptively marketing addictive painkillers, a sum substantially less than investors expected, driving up J&J shares.
Lawmakers on the U.S. Senate Judiciary Committee urged the Trump administration to conduct a scientific review of a Justice Department-backed bill to classify all illicit chemical knockoffs of the potent painkiller fentanyl in the same legal category as heroin.
Teva Pharmaceutical agreed to pay an $85 million settlement with the state of Oklahoma days before the company was set to face trial over allegations that the world’s largest generic manufacturer and other drugmakers helped fuel the U.S. opioid epidemic.